Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBI-940
- Development stage
- Discontinued
- Lead developer
- Boundless Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BBI-940 is a novel, orally bioavailable, highly selective kinesin degrader developed by Boundless Bio. It targets a previously undrugged kinesin protein that plays a critical role in DNA segregation during mitosis, including the segregation of extrachromosomal DNA (ecDNA), which is implicated in oncogene amplification and cancer progression. Preclinical studies have demonstrated potent anti-tumor activity for BBI-940 as a single agent, including tumor regression in mouse xenograft models of cancer. The drug represents the lead candidate from Boundless Bio’s Kinesin program and is positioned as a first-in-class therapy aimed at disrupting ecDNA-driven oncogenic processes in solid tumors[3][6][8].
Beyond the preview
Go deeper on BBI-940.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBI-940.